托珠单抗治疗难治性巨细胞动脉炎:单药与联合传统免疫抑制剂的多中心观察研究
该多中心观察研究比较了托珠单抗单药与联合传统免疫抑制剂治疗134例难治性巨细胞动脉炎患者的疗效与安全性。联合组患者更年轻、基线CRP更高且颅外大血管受累更常见,但12个月时两组改善相似,联合组持续缓解率显著更高,复发和严重不良事件无差异。
要点
- 托珠单抗单药或联合传统免疫抑制剂治疗难治性GCA均有效且安全。
- 联合组12个月持续缓解率显著高于单药组,尽管其基线病情更重。
- 两组复发率和严重不良事件发生率相似。
核心结论
- 在临床实践中,托珠单抗单药或联合传统免疫抑制剂治疗难治性巨细胞动脉炎均有效且安全。
- 联合免疫抑制剂(通常为甲氨蝶呤)似乎可使持续缓解率更高,即使在病程更长、颅外大血管受累更多和急性期反应物更高的患者中。
研究设计与样本
- 多中心观察研究,纳入134例难治性巨细胞动脉炎患者。
- 托珠单抗单药组82例,联合传统免疫抑制剂组52例;联合药物包括甲氨蝶呤48例、硫唑嘌呤3例、来氟米特1例。
- 主要结局为持续缓解(临床和实验室参数正常至少6个月)和复发次数。
主要发现
- 联合组患者更年轻(68.8 ± 8.0 vs 71.2 ± 9.0岁;p=0.04)。
- 联合组C反应蛋白水平更高(2.1[1-4.7] vs 1.2[0.2-2.4] mg/dL;p=0.003)。
- 联合组颅外大血管 vasculitis 患病率更高(57% vs 34.1%;p=0.007)。
- 两组12个月时改善相似,但联合组12个月持续缓解率显著更高。
- 两组复发和严重不良事件相似。
关键数值与推荐
- 持续缓解定义为临床和实验室参数正常至少6个月。
- 联合组12个月持续缓解率显著高于单药组。
- 两组复发率和严重不良事件发生率无显著差异。
临床怎么用
- 对于难治性巨细胞动脉炎,托珠单抗单药或联合传统免疫抑制剂均可作为有效且安全的选择。
- 对于病程较长、颅外大血管受累或炎症指标较高的患者,联合传统免疫抑制剂可能提高持续缓解率。
局限性
- 本研究为观察性多中心研究,非随机对照设计,存在选择偏倚可能。
- 联合组样本量较小(52例),且联合药物以甲氨蝶呤为主,其他药物例数少。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To compare the efficacy and safety of TCZ in monotherapy (TCZMONO) vs. combined with conventional immunosuppressive drugs (TCZCOMBO) in Giant Cell Arteritis (GCA) in a clinical practice scenario. METHODS: Multicenter study of 134 patients with refractory GCA. Patients on TCZMONO (n = 82) were compared with those on TCZCOMBO (n = 52). Drugs were methotrexate (MTX) (n = 48), azathioprine (n = 3), and leflunomide (n = 1). The main outcomes were: prolonged remission (normalization of clinical and laboratory parameters for at least 6 months) and the number of relapses. RESULTS: Patients on TCZCOMBO were younger (68.8 ± 8.0 vs 71.2 ± 9.0 years; p = 0.04), with a trend to a longer GCA duration (median [IQR],18.5 [6.25-34.0] vs. 13.0 [7.75-33.5] months; p = 0.333), higher C-reactive protein (CRP) levels (2.1[1-4.7] vs 1.2 [0.2-2.4] mg/dL; p = 0.003), and more prevalence of extra-cranial large-vessel vasculitis (LVV) (57% vs. 34.1%; p = 0.007). In both groups, rapid and sustained improvement was observed. Despite the longer GCA duration, and the higher CRP levels and prevalence of LVV in the TCZCOMBO, the improvement was similar in both groups at 12 months. Moreover, in the TCZCOMBO group, prolonged remission was significantly higher at 12-month. Relapses and serious adverse events were similar in both groups. CONCLUSION: In clinical practice, TCZ in monotherapy or combined with conventional immunosuppressive agents is effective and safe in patients with GCA. Nevertheless, the addition of immunosuppressive drugs, usually MTX, seems to allow a higher rate of prolonged remission, even in patients with a longer GCA duration, more extra-cranial LVV involvement, and higher acute-phase reactants.
引用
- Calderón-Goercke M, Castañeda S, Aldasoro V, et al. Tocilizumab in refractory giant cell arteritis. Monotherapy versus combined therapy with conventional immunosuppressive drugs. Observational multicenter study of 134 patients. Semin Arthritis Rheum. 2021. PMID: 33607384. doi:10.1016/j.semarthrit.2021.01.006
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。